CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
超越扩增：肿瘤减积是提升淋巴瘤 CAR-T 细胞潜力的关键
英文原题：Beyond Expansion: Tumor Debulking as Key to Improving CAR T-Cell Potential in Lymphoma.
查看英文原题
Beyond Expansion: Tumor Debulking as Key to Improving CAR T-Cell Potential in Lymphoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
在本期《Blood Cancer Discovery》中，Pomeroy及其同事探索了axi-cel在LBCL中的群体药代动力学/药效学模型，量化了在CAR-T 细胞输注前进行肿瘤减积如何能够显著提高持久缓解率。他们的框架整合了CAR-T 细胞生物学和治疗的机制建模原则，如CAR-T 细胞扩增、结合、杀伤和随机CD19丢失，为优化联合方案和未来试验设计提供了可操作的见解。参见Pomeroy等人的相关文章，第41页。
展开英文摘要原文
In this issue of Blood Cancer Discovery, Pomeroy and colleagues explore a population pharmacokinetic/pharmacodynamic model of axicabtagene ciloleucel in large B-cell lymphoma, quantifying how tumor debulking before chimeric antigen receptor (CAR) T-cell infusion can significantly improve durable remission rates.
Their framework incorporates mechanistic modeling principles of CAR T-cell biology and therapy, such as CAR T-cell expansion, binding, killing, and stochastic CD19 loss, providing actionable insights for optimizing combination approaches and future trial design. See related article by Pomeroy et al. , p. 41.
论文信息
- 作者
- Altrock PM
- 单位
- Department of Hematology and Oncology, Clinical Research Unit CATCH-ALL, University Hospital Schleswig-Holstein, Kiel University, Kiel, Germany.Germany
- 期刊
- Blood cancer discovery2026 Jan 12
- 原文标识
- PubMed 41263639 · DOI 10.1158/2643-3230.BCD-25-0397